Revelation Biosciences, Inc., a Delaware corporation, was founded on November 20, 2019. The company is a clinical-stage life sciences company focused on developing immunotherapies for the prevention and treatment of diseases. Revelation has several product candidates in development. REVTx-99 is the primary therapeutic candidate and is an intranasal immunomodulator for the prevention or treatment of infections caused by various respiratory viruses. REVTx-99 is also being developed for other indications such as allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjuvant that can be used in combination with an intramuscular vaccine for more complete immunity. Revelation is also developing REVDx-501, a rapid home diagnostic tool that can be used to detect any respiratory viral infection without the need for specialized instruments.